Commission fines pharmaceutical companies for drug-delay deals

463 views · Published 10 July 2014 · 1:54 · Indexed 23 October 2026

Channel: Rapporteur News · 2014 · News & Politics

Watch on YouTube

The European Commission on Wednesday imposed fines totaling €427.7 million on the French pharmaceutical company Servier and five producers of generic medicines -- Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin -- for concluding a series of deals of deals all aimed at protecting Servier's bestselling blood pressure medicine, perindopril, from price competition by generics in the EU. 

Through a technology acquisition and a series of patent settlements with generic rivals, Servier implemented a strategy to exclude competitors and delay the entry of cheaper generic medicine to the detriment of public budgets and patients in breach of EU antitrust rules. 

More from this channel